Biomodulation Of 5fu

Biomodulation is a strategy that involves the alteration of tumor cell susceptibility to anticancer drugs through the modification of biochemical pathways to produce an accentuated or selective action on the cancer cells. This approach differs from that of combination chemotherapy because the biomodulator is not a cytotoxic agent. The most widespread use of biomodulation involves the use of leucovorin (LV) to increase intracellular folate cofac-tors and, thus, enhance the binding of...

Combined Locoregional And Systemic Chemotherapy

The rationale for combining locoregional and systemic chemotherapy in advanced col-orectal cancer with metastases to the liver only is based on the following issues 1. Locoregional chemotherapy has a well-defined activity in these patients and is possibly superior, as reported above, to systemic treatment (at least when traditional agents are administered intravenously). 2. The two therapeutic modalities have nonoverlapping side-effects (liver toxicity for intraarterial therapy, chiefly when...

References

Molecular bases for circadian clocks. Cell 1999 96(2) 271-290. 2. Shearman LP, Sriram S, Weaver DR, et al. Interacting molecular loops in the mammalian circadian clock. Science 2000 288 1013-1019. 3. Cermakian N, Sassone-Corsi P. Multilevel regulation of the circadian clock. Nature Rev Mol Cell Biol 2000 1 59-67. 4. Lowrey PL, Takahashi JS. Genetics of the mammalian circadian system photic entrainment, circadian pacemaker mechanisms and posttranslational regulation. Ann Rev Genetics...

Clinical Pharmacology Trials

UFT in a dose range of 100-400 mg results in linear plasma exposures of tegafur, uracil, and 5-FU. In order to assess the pharmacokinetics of single- and continuous-dose UFT, patients with metastatic colorectal cancer initally received a single dose of UFT at either 100, 200, or 400 mg, accompanied by LV 25 mg orally, followed, after 7 d of rest, by treatment with UFT 300 mg m2 plus LV 75 mg d. After single-dosing, the plasma concentrations of tegafur, 5-FU, and uracil rose rapidly, reaching...

Clinical Chronopharmacology

Rhythm in 5-FU Pharmacokinetics 5-FU 15 mg kg, e.g., approx 600 mg m2 was injected intravenously bolus at 01 00, 07 00, 13 00 or 19 00 h to 28 patients with metastatic gastrointestinal cancer in a randomized sequence, each injection being separated by 96 h from the next one. Both plasma pharmacokinetics and hematologic toxicity were assessed. 5-FU dosing at 01 00 h resulted in the longest half-life, in the largest VdSS and AUC, and in the lowest clearance CIB , as well as in the least...